These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 8026158)

  • 1. Postantibiotic effect of DU-6859a and levofloxacin as compared with ofloxacin.
    Houston AK; Jones RN
    Diagn Microbiol Infect Dis; 1994 Jan; 18(1):57-9. PubMed ID: 8026158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of growth conditions on antimicrobial activity of DU-6859a and its bactericidal activity determined by the killing curve method.
    Tanaka M; Hoshino K; Hohmura M; Ishida H; Kitamura A; Sato K; Hayakawa I; Nishino T
    J Antimicrob Chemother; 1996 Jun; 37(6):1091-102. PubMed ID: 8836812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.
    Giamarellos-Bourboulis EJ; Sambatakou H; Grecka P; Giamarellou H
    Eur J Clin Microbiol Infect Dis; 1998 Sep; 17(9):657-61. PubMed ID: 9832270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bactericidal activity of the new 4-quinolones DU-6859a and DV-7751a.
    Morrissey I; Smith JT
    J Med Microbiol; 1995 Jul; 43(1):4-8. PubMed ID: 7608954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postantibiotic, postantibiotic sub-MIC, and subinhibitory effects of PGE-9509924, ciprofloxacin, and levofloxacin.
    Odenholt I; Löwdin E; Cars O
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3352-6. PubMed ID: 14506057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimum inhibitory concentration quality-control guidelines for biapenem, DU-6859a, FK-037, levofloxacin, grepafloxacin, and ceftizoxime when using various National Committee for Clinical Laboratory Standards susceptibility test methods. Quality Control Study Group.
    Bale MJ; Jones RN; Erwin ME
    Diagn Microbiol Infect Dis; 1994 May; 19(1):65-8. PubMed ID: 7956017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin).
    Cormican MG; Marshall SA; Jones RN
    Diagn Microbiol Infect Dis; 1995 Jan; 21(1):51-4. PubMed ID: 7789097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postantibiotic effects of E-4868 and OPC-17116.
    Sanford MD; Jones RN
    J Antimicrob Chemother; 1993 Dec; 32(6):916-7. PubMed ID: 8144440
    [No Abstract]   [Full Text] [Related]  

  • 9. [In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
    Shimizu M; Tabata M; Hara T; Araake M; Watabe H; Nishino T
    Jpn J Antibiot; 2002 Dec; 55(6):791-9. PubMed ID: 12621733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of two novel fluoroquinolones (DU-6859a and DV-7751a) tested against glycopeptide-resistant enterococcal isolates.
    Jones RN; Johnson DM; Biedenbach DJ; Marshall SA
    Diagn Microbiol Infect Dis; 1995 Nov; 23(3):123-7. PubMed ID: 8849658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro antibacterial activity of DU-6859a, a new fluoroquinolone.
    Nakane T; Iyobe S; Sato K; Mitsuhashi S
    Antimicrob Agents Chemother; 1995 Dec; 39(12):2822-6. PubMed ID: 8593031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the postantibiotic and postantibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureus and Streptococcus pneumoniae.
    Licata L; Smith CE; Goldschmidt RM; Barrett JF; Frosco M
    Antimicrob Agents Chemother; 1997 May; 41(5):950-5. PubMed ID: 9145850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci.
    Spangler SK; Lin G; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1998 May; 42(5):1253-5. PubMed ID: 9593160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones.
    Thomson KS; Sanders CC
    J Antimicrob Chemother; 1998 Aug; 42(2):179-87. PubMed ID: 9738835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in vitro activities of DU-6859a, levofloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against 387 aerobic and anaerobic bite wound isolates.
    Goldstein EJ; Citron DM; Hunt Gerardo S; Hudspeth M; Merriam CV
    Antimicrob Agents Chemother; 1997 May; 41(5):1193-5. PubMed ID: 9145900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA.
    McCloskey L; Moore T; Niconovich N; Donald B; Broskey J; Jakielaszek C; Rittenhouse S; Coleman K
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():13-21. PubMed ID: 10824027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postantibiotic effect of ciprofloxacin compared with that of five other quinolones.
    Minguez F; Ramos C; Barrientos S; Loscos A; Prieto J
    Chemotherapy; 1991; 37(6):420-5. PubMed ID: 1760941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
    Tomioka H; Sato K; Akaki T; Kajitani H; Kawahara S; Sakatani M
    Antimicrob Agents Chemother; 1999 Dec; 43(12):3001-4. PubMed ID: 10582897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
    Bauernfeind A
    J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic effects of a new quinolone, DU-6859a, on polymicrobial infections in a newly designed model of rat uterine endometritis.
    Mikamo H; Kawazoe K; Sato Y; Izumi K; Tamaya T
    J Antimicrob Chemother; 1998 Jan; 41(1):131-3. PubMed ID: 9511050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.